Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 1/20 | 0.63 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.63 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.63 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.63 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.63 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.63 |
| ▸ | PDE10A | Q9Y233 | 12/20 | 0.63 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 5/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.58 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.58 |
| ▸ | BRAF | P15056 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17088189 | 1.00 | MAPK13 (0.63) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL17088199 | 0.84 | MEN1 (0.66) | CSNK1DCSNK1EPDE10ABRAF | |
| SCHEMBL3276042 | 0.83 | PDE10A (0.69) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| SCHEMBL17088195 | 0.83 | SLC6A3 (0.69) | PDE10A | |
| SCHEMBL17088197 | 0.83 | SLC6A3 (0.69) | PDE10A | |
| SCHEMBL5258392 | 0.79 | MAPK13 (0.74) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL3270632 | 0.79 | PDE10A (0.76) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| SCHEMBL3270981 | 0.78 | CSNK1D (0.68) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 | |
| SCHEMBL28616735 | 0.78 | TUBB4A (0.53) | MAPK14PDE10APDE4APDE4BPDE3B | |
| SCHEMBL5450262 | 0.78 | MAPK13 (0.72) | MAPK13CSNK1DCSNK1EMAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160058894-A1 | RADIOLABELED PDE10A LIGANDS | ABBVIE DEUTSCHLAND (DE) | 2016-03-03 | — | — | US | disclosed |
| US-9138494-B2 | Radiolabeled PDE10A ligands | ABBVIE INC. (US) | 2015-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058894-A1 | RADIOLABELED PDE10A LIGANDS | PDE10A, PDE3A, PDE5A | MAPK13 2582/4885CSNK1D 1230/4885CSNK1E 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.